PMID- 29608324
OWN - NLM
STAT- MEDLINE
DCOM- 20190425
LR  - 20190425
IS  - 0894-203X (Print)
IS  - 0894-203X (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan
TI  - The devil is in the details: retention of recipient group A type 5 years after a 
      successful allogeneic bone marrow transplant from a group O donor.
PG  - 19-22
AB  - ABO-incompatible (ABOi) hematopoietic stem cell transplants (HSCTs) can present 
      challenges in the blood bank. During transplantation, patients receive components 
      that are ABO-compatible with both the donor graft and recipient; this practice 
      can strain group O red blood cell (RBC) inventories.1 In addition, there are 
      risks for acute hemolysis at the time of infusion and in the early 
      post-transplant period.1,2 In ABO major-incompatible bone marrow HSCTs, which 
      contain significant quantities of donor RBCs that are ABOi with recipient plasma, 
      it is common to perform a RBC depletion of the bone marrow in an effort to 
      minimize hemolysis at the time of infusion.2 Furthermore, patients with 
      high-titer ABO antibodies may undergo a prophylactic, pre-transplant plasma 
      exchange to further reduce the risk of acute hemolysis, delayed RBC engraftment, 
      and pure RBC aplasia.2-4 ABO minor-incompatible HSCTs, in which donor plasma is 
      ABOi with the recipient, have less risk for hemolysis at the time of infusion but 
      can result in transient hemolysis approximately 10-21 days post-transplant, 
      especially in patients undergoing nonmyeloablative HSCT and/or patients who have 
      not received methotrexate for graft-versus-host-disease (GVHD) prophylaxis.1-4 In 
      these patients, viable donor B-lymphocytes in the graft may expand and produce 
      ABO antibodies capable of hemolyzing patient RBCs.
FAU - Cooling, Laura L W
AU  - Cooling LLW
AD  - Michigan Medicine University of Michigan 2F225 UH-Blood Bank Ann Arbor, MI.
FAU - Herrst, Michelle
AU  - Herrst M
AD  - Michigan Medicine University of Michigan Ann Arbor, MI.
FAU - Hugan, Sherri L
AU  - Hugan SL
AD  - Michigan Medicine University of Michigan Ann Arbor, MI.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Immunohematology
JT  - Immunohematology
JID - 8806387
RN  - 0 (ABO Blood-Group System)
SB  - IM
MH  - ABO Blood-Group System
MH  - Blood Group Incompatibility
MH  - *Bone Marrow Transplantation
MH  - *Graft vs Host Disease
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
EDAT- 2018/04/03 06:00
MHDA- 2019/04/26 06:00
CRDT- 2018/04/03 06:00
PHST- 2018/04/03 06:00 [entrez]
PHST- 2018/04/03 06:00 [pubmed]
PHST- 2019/04/26 06:00 [medline]
PST - ppublish
SO  - Immunohematology. 2018 Jan;33(1):19-22.